Post-essential Thrombocythemia Myelofibrosis
Showing 26 - 50 of >10,000
Primary Myelofibrosis Trial (Pacritinib)
Withdrawn
- Primary Myelofibrosis
- Pacritinib
- (no location specified)
May 3, 2021
Chronic Phase Myelofibrosis, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis Trial in Boston, Bronx, New
Completed
- Chronic Phase Myelofibrosis
- +3 more
-
Boston, Massachusetts
- +2 more
May 27, 2021
Primary Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis Trial in Worldwide (RO7490677,
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis, Postessential Thrombocythemia (Post-ET)
Completed
- Primary Myelofibrosis (PMF)
- +2 more
-
Phoenix, Arizona
- +12 more
Jan 12, 2021
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis Trial in Worldwide
Recruiting
- Primary Myelofibrosis
- +2 more
- Pacritinib
- Physician's Choice medications
-
Birmingham, Alabama
- +151 more
Aug 22, 2022
Myelofibrosis Trial in Stanford, Ann Arbor (Idelalisib, Ruxolitinib)
Terminated
- Myelofibrosis
-
Stanford, California
- +1 more
Aug 31, 2020
Primary Myelofibrosis, Post-Polycythemia Vera, Post-Essential Thrombocytopenia Trial in United States (Panobinostat)
Terminated
- Primary Myelofibrosis
- +2 more
-
Scottsdale, Arizona
- +8 more
Jul 9, 2021
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary
Recruiting
- Myelofibrosis Transformation in Essential Thrombocythemia
- +2 more
- Elotuzumab
- Questionnaire Administration
-
Houston, TexasM D Anderson Cancer Center
Feb 17, 2021
Polycythemia Vera, Essential Thrombocythemia, and
Not yet recruiting
- Myeloproliferative Neoplasm
- Next-generation sequencing
- (no location specified)
Jun 27, 2022
Myeloproliferative Disorders, Essential Thrombocythemia, Tumors Trial (JNJ-88549968)
Not yet recruiting
- Myeloproliferative Disorders
- +3 more
- (no location specified)
Nov 21, 2023
Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis Trial in Buffalo (drug, dietary supplement, other)
Terminated
- Essential Thrombocythemia
- +2 more
- Arsenic Trioxide
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 20, 2022
Myeloproliferative Tumor, MPN, Essential Thrombocythemia Trial in Orange (N-Acetylcysteine)
Active, not recruiting
- Myeloproliferative Neoplasm
- +4 more
-
Orange, CaliforniaChao Family Comprehensive Cancer Center, University of Californi
Jan 6, 2023
Myeloproliferative Tumor, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage Trial (CALR allele burden
Recruiting
- Myeloproliferative Neoplasm
- +3 more
- CALR allele burden quantification
-
Angers, FranceCHU Angers
Nov 2, 2022
Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,
Recruiting
- Acute Myeloid Leukemia
- +8 more
- Decitabine
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 18, 2022
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis Trial in Worldwide
Terminated
- Primary Myelofibrosis
- +2 more
- Pacritinib
- Best Available Therapy
-
Scottsdale, Arizona
- +121 more
Oct 21, 2021
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Trial
Completed
- Primary Myelofibrosis (PMF)
- +2 more
- Momelotinib
- Best Available Therapy (BAT)
-
Los Angeles, California
- +47 more
Apr 1, 2020